Connelly Deirdre P 4
4 · Sarepta Therapeutics, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sarepta (SRPT) Director Deirdre P. Connelly Receives RSU Award
What Happened Deirdre P. Connelly, a director of Sarepta Therapeutics, was granted 16,875 restricted stock units (RSUs) on 2026-06-04 (reported on Form 4 filed 2026-06-05). The award is an equity grant (code A); no per-share price or total dollar amount is listed in the filing. RSUs represent the right to receive one share of common stock each upon vesting.
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears timely).
- Transaction type/code: Grant/Award (A).
- Shares/units granted: 16,875 RSUs; price: N/A (grant).
- Shares owned following the transaction: Not specified in this filing.
- Footnote: RSUs vest on the earlier of the one‑year anniversary of the grant date and the next annual meeting of stockholders that is at least 50 weeks after the prior meeting.
- No indication of a 10b5-1 plan, sale, exercise, or tax‑withholding reported in this Form 4.
Context RSU grants to directors are a common form of compensation and do not represent an immediate market purchase or sale — they convert to shares only when vested. To estimate the grant’s market value, multiply 16,875 by Sarepta’s share price on or shortly after 2026-06-04. The filing itself is factual and does not state any intent or market sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-04+16,875→ 22,100 total
Footnotes (1)
- [F1]The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.